Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells

Cytokine

Volumn 56, Issue 2, 2011, Pages 365-375

  Wang, Yue ^a,b   Qu, Ye ^a   Niu, Xiu Long ^a   Sun, Wei Jia ^a   Zhang, Xiao Lei ^a   Li, Ling Zhi ^a,b  

^a MEDICAL COLLEGE OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^b Tianjin Key Laboratory for Biomarkers of Occupational and Environmental Hazard   (China)

Author keywords

Apoptosis inhibitory proteins; Chemoresistance; Interleukin 8 (IL 8); Mutidrug resistance related genes; Ovarian cancer (OVCA)

Indexed keywords

CASPASE 3; CISPLATIN; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; RAS PROTEIN; RECOMBINANT INTERLEUKIN 8; X LINKED INHIBITOR OF APOPTOSIS;

ARTICLE; AUTOCRINE EFFECT; CANCER CELL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG CYTOTOXICITY; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IC 50; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STRAIN DIFFERENCE;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CISPLATIN; DNA PRIMERS; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-8; OVARIAN NEOPLASMS; PACLITAXEL; POLYMERASE CHAIN REACTION;

EID: 80053326169     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.06.005     Document Type: Article

References (55)

1. Risch H.A. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998, 90:1774-1786.
2. Agarwal R., Kaye S.B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003, 3:502-516.
3. Richardson A., Kaye S.B. Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance. Drug Resist Updat 2005, 8:311-321.
4. Walz A., Peveri P., Aschauer H., Baggiolini M. Purification and amino acid sequencing of NAF, a novel neutrophil-activating factor produced by monocytes. Biochem Biophys Res Commun 1987, 149:755-761.
5. Schroder J.M., Christophers E. Identification of C5ades arg and an anionic neutrophil-activating peptide (ANAP) in psoriatic scales. J Invest Dermatol 1986, 87:53-58.
6. Matsushima K., Oppenheim J.J. Interleukin 8 and MCAF: novel inflammatory cytokines inducible by IL1 and TNF. Cytokine 1989, 1:2-13.
7. Roebuck K.A. Regulation of interleukin-8 gene expression. J Interferon Cytokine Res 1999, 19:429-438.
8. Waugh D.J.J., Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008, 14:6735-6741.
9. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 2001, 12:375-391.
10. Tanaka T., Bai Z., Srinoulprasert Y., Yang B., Hayasaka H., Miyasaka M. Chemokines in tumor progression and metastasis. Cancer Sci 2005, 96:317-322.
11. Ivarsson K., Runesson E., Sundfeldt K., Haeger M., Hedin L., Janson P.O., et al. The chemotactic cytokine interleukin-8 - a cyst fluid marker for malignant epithelial ovarian cancer?. Gynecol Oncol 1998, 71:420-423.
12. Ivarsson K., Ekerydh A., Fyhr I.M., Janson P.O., Brännström M. Upregulation of interleukin-8 and polarized epithelial expression of interleukin-8 receptor A in ovarian carcinomas. Acta Obstet Gynecol Scand 2000, 79:777-784.
13. Fasciani A., D'Ambrogio G., Bocci G., Luisi S., Artini P.G., Genazzani A.R. Vascular endothelial growth factor and interleukin-8 in ovarian cystic pathology. Fertil Steril 2001, 75:1218-1221.
14. Herrera C.A., Xu L., Bucana C.D., Silvael V.G., Hess K.R., Gershenson D.M., et al. Expression of metastasis-related genes in human epithelial ovarian tumors. Int J Oncol 2002, 20:5-13.
15. Kassim S.K., El-Salahy E.M., Fayed S.T., Helal S.A., Helal T., Azzam Eel-D, et al. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem 2004, 37:363-369.
16. Lokshin A.E., Winans M., Landsittel D., Marrangoni A.M., Velikokhatnaya L., Modugno F., et al. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol Oncol 2006, 102:244-251.
17. Giuntoli R.L., Webb T.J., Zoso A., Rogers O., Diaz-Montes T.P., Bristow R.E., et al. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res 2009, 29:2875-2884.
18. Nowak M., Glowacka E., Szpakowski M., Szyllo K., Malinowski A., Kulig A., et al. Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors. Neuro Endocrinol Lett 2010, 31:375-383.
19. Penson R.T., Kronish K., Duan Z., Feller A.J., Stark P., Cook S.E., et al. Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 2000, 10:33-41.
20. Uslu R., Sanli U.A., Dikmen Y., Karabulut B., Ozsaran A., Sezgin C., et al. Predictive value of serum interleukin-8 levels in ovarian cancer patients treated with paclitaxel-containing regimens. Int J Gynecol Cancer 2005, 15:240-245.
21. Mayerhofer K., Bodner K., Bodner-Adler B., Schindl M., Kaider A., Hefler L., et al. Interleukin-8 serum level shift in patients with ovarian carcinoma undergoing paclitaxel-containing chemotherapy. Cancer 2001, 91:388-393.
22. Merritt W.M., Lin Y.G., Spannuth W.A., Fletcher M.S., Kamat A.A., Han L.Y., et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst 2008, 100:359-372.
23. Wang Y., Yang J., Gao Y., Dong L.J., Liu S., Yao Z. Reciprocal regulation of 5alpha-dihydrotestosterone, interleukin-6 and interleukin-8 during proliferation of epithelial ovarian carcinoma. Cancer Biol Ther 2007, 6:864-871.
24. Yang J., Wang Y., Gao Y., Shao J., Zhang X.J., Yao Z. Reciprocal regulation of 17beta-estradiol, interleukin-6 and interleukin-8 during growth and progression of epithelial ovarian cancer. Cytokine 2009, 46:382-391.
25. Duan Z., Feller A.J., Penson R.T., Chabner B.A., Seiden M.V. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res 1999, 5:3445-3453.
26. Murdoch C., Monk P.N., Finn A. Cxc chemokine receptor expression on human endothelial cells. Cytokine 1999, 11:704-712.
27. Xu L., Fidler I.J. Interleukin 8: an autocrine growth factor for human ovarian cancer. Oncol Res 2000, 12:97-106.
28. Hayakawa J., Ohmichi M., Kurachi H., Kanda Y., Hisamoto K., Nishio Y., et al. Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res 2000, 60:5988-5994.
29. Mabuchi S., Ohmichi M., Kimura A., Hisamoto K., Hayakawa J., Nishio Y., et al. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem 2002, 277:33490-33500.
30. Ohta T., Ohmichi M., Hayasaka T., Mabuchi S., Saitoh M., Kawagoe J., et al. Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models. Endocrinology 2006, 147:1761-1769.
31. Hu L., Hofmann J., Lu Y., Mills G.B., Jaffe R.B. Inhibition of phosphatidylinositol 3-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res. 2002, 62:1087-1092.
32. Hayakawa J., Ohmichi M., Kurachi H., Ikegami H., Kimura A., Matsuoka T., et al. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J Biol Chem 1999, 274:31648-31654.
33. Persons D.L., Yazlovitskaya E.M., Cui W., Pelling J.C. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin Cancer Res 1999, 5:1007-1014.
34. Lee S., Yoon S., Kim D.H. A high nuclear basal level of ERK2 phosphorylation contributes to the resistance of cisplatin-resistant human ovarian cancer cells. Gynecol Oncol 2007, 104:338-344.
35. Wang Y., Niu X., Qu Y., Wu J., Zhu Y., Sun W., et al. Autocrine production of Interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett 2010, 295:110-123.
36. Eliopoulos A.G., Kerr D.J., Herrod J., Hodgkins L., Krajewski S., Reed J.C., et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and bcl-2. Oncogene 1995, 11:1217-1228.
37. Williams J., Lucas P.C., Griffith K.A., Choi M., Fogoros S., Hu Y.Y., et al. Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol 2005, 96:287-295.
38. Zhang B., Pan J.S., Liu J.Y., Han S.P., Hu G., Wang B. Effects of chemotherapy and/or radiotherapy on survivin expression. Methods Find Exp Clin Pharmacol 2006, 28:619-625.
39. Sasaki H., Sheng Y., Kotsuji F., Tsang B.K. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res 2000, 60:5659-5666.
40. Hayakawa J., Ohmichi M., Kurachi H., Ikegami H., Kimura A., Matsuoka T., et al. Inhibition of extracellular signal regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J Biol Chem 1999, 274:31648-31654.
41. Sharp S.Y., Smith V., Hobbs S., Kelland L.R. Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines. Br J Cancer 1998, 78:175-180.
42. Zigler M., Villares G.J., Lev D.C., Melnikova V.O., Bar-Eli M. Tumor immunotherapy in melanoma: strategies for overcoming mechanisms of resistance and escape. Am J Clin Dermatol 2008, 9:307-311.
43. Ning Y., Manegold P.C., Hong Y.K., Zhang W., Pohl A., Lurje G., et al. Interleukin-8 is associated with proliferation, migration, angiogenesis, chemosensitivity in vitro, in vivo in colon cancer cell line models. Int J Cancer 2010, 20. [Epub ahead of print].
44. Huang D., Ding Y., Zhou M., Rini B.I., Petillo D., Qian C.N., et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 2010, 70:1063-1071.
45. Araki S., Omori Y., Lyn D., Singh R.K., Meinbach D.M., Sandman Y., et al. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res 2007, 67:6854-6862.
46. Singh R.K., Lokeshwar B.L. Depletion of intrinsic expression of Interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs. Mol Cancer 2009, 8:57.
47. Brat D.J., Bellail A.C., Van Meir E.G. The role of Interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro-oncol 2005, 7:122-133.
48. Baekelandt M.M., Holm R., Nesland J.M., Tropé C.G., Kristensen G.B. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res 2000, 20:1061-1067.
49. Goff B.A., Paley P.J., Greer B.E., Gown A.M. Evaluation of chemoresistance markers in women with epithelial ovarian carcinoma. Gynecol Oncol 2001, 81:18-24.
50. Yakirevich E., Sabo E., Naroditsky I., Sova Y., Lavie O., Resnick M.B. Multidrug resistance-related henotype and apoptosis-related protein expression in ovarian serous carcinomas. Gynecol Oncol 2006, 100:152-159.
51. Zhang T., Guan M., Jin H.Y., Lu Y. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells. Gynecol Oncol 2005, 97:501-507.
52. Wilson C., Purcell C., Seaton A., Oladipo O., Maxwell P.J., O'Sullivan J.M., et al. Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis. J Pharmacol Exp Ther 2008, 327:746-759.
53. Arimoto-Ishida E., Ohmichi M., Mabuchi S., Takahashi T., Ohshima C., Hay-akawa J., et al. Inhibition of phosphorylation of a forkhead transcription factor sensitizes human ovarian cancer cells to cisplatin. Endocrinology 2004, 145:2014-2022.
54. Mabuchi S., Ohmichi M., Nishio Y., Hayasaka T., Kimura A., Ohta T., et al. Inhibition of NFkB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem 2004, 279:23477-23485.
55. MacManus C.F., Pettigrew J., Seaton A., Wilson C., Maxwell P.J., Berlingeri S., et al. Interleukin-8 signaling promotes translational of regulation cyclin D in androgen-independent prostate cancer cells. Mol Cancer Res 2007, 5:737-748.